A human anti-IL-6R monoclonal IgG1 antibody.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Sarilumab is a human monoclonal IgG1 antibody that binds to interleukin 6 receptor (IL-6R), thus blocking IL-6 mediated inflammatory response. Sarilumab is approved for the treatment of moderate to severe rheumatoid arthritis (DrugBank).

Sarilumab on Wikipedia




Supporting references

Link Tested on Impact factor Notes Publication date
Sarilumab use in severe SARS-CoV-2 pneumonia
Severe severity Preprint
Patients May/18/2020
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
IL-6 Case series Antibody
Patients 9.91

Potential clinical benefit in the case of early administration. Rapid improvement in respiratory function and inflammation markers in 10 out of 15 patients. Sample size: 15. Dosage: Subcutaneous injection of 400 mg; 3 of 15 patients received a second dose within 24 hours of the first.

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
IL-6 IL-1 ARDS Severe severity Protein factor Critical severity Antibody Cohort study
Severe pneumonia and hyper-inflammation patients 7.56

The therapy increased survival in patients when initiated while PaO2/FiO2 ≥ 100 mmHg (but not if lower). Sample size: 25 + 103 matched control. Dosage: A single 400 mg IV dose. 

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
IL-6 IL-1 Protein factor Antibody Cohort study
Patients with respiratory insufficiency and hyperinflammation 8.14

The treatment (data pooled for Tocilizumab and Sarilumab) did not significantly reduce mortality in the studied population. It was effective in the sub-cohorts of patients with either high levels of C-reactive protein or low levels of lactate dehydrogenase, however. Sample size: 26 (+ 29 pooled with Tocilizumab) + 275 no IL-inhibitor. Dosage: A single IV dose of 400 mg. Main outcome: Survival.


Clinical trials

ID Title Status Phase Start date Completion date
NCT04322773 Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure Terminated Phase 2 Apr/05/2020 Oct/08/2020
  • Alternative id - APPI2-CV-2020-01
  • Interventions - Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 20
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events
NCT04357860 Clinical Trial of Sarilumab in Adults With COVID-19 Completed Phase 2 Apr/28/2020 Apr/06/2021
  • Alternative id - SARICOR
  • Interventions - Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario Reina Sofía, Córdoba, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Ventilation requirements|Crude mortality|Time to clinical improvement|Time until improvement in oxygenation|Proportion of patients requiring invasive mechanical ventilation|Proportion of patients having negative COVID-19 CRP at each visit|Mean of serum cytokine levels|Adverse events related to medication and its administration|Incidence in the appearance of serious bacterial, fungal or opportunistic infections|Incidence of perforation of the gastrointestinal tract|Leukocyte and neutrophil count|Hemoglobin levels|Platelet count|Levels of creatinemia|Bilirubin levels|ALT and AST levels